【8月6日中国生物制药罗伐昔替尼Ⅲ期临床试验启动受试者招募】8月6日,中国生物制药公告透露,罗伐昔替尼用于治疗中重度cGVHD的Ⅲ期临床试验,目前正处于受试者招募阶段。该集团表示,将加快罗伐昔替尼的全球临床开发进程,以便尽早为全球患者提供更优质的治疗方案。本文由 AI 算法生成,仅作参考,不涉投资建议,使用风险自担
Source Link【8月6日中国生物制药罗伐昔替尼Ⅲ期临床试验启动受试者招募】8月6日,中国生物制药公告透露,罗伐昔替尼用于治疗中重度cGVHD的Ⅲ期临床试验,目前正处于受试者招募阶段。该集团表示,将加快罗伐昔替尼的全球临床开发进程,以便尽早为全球患者提供更优质的治疗方案。本文由 AI 算法生成,仅作参考,不涉投资建议,使用风险自担
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.